argenx (NASDAQ:ARGX) Price Target Raised to $720.00 at HC Wainwright

argenx (NASDAQ:ARGX) had its price objective hoisted by HC Wainwright from $717.00 to $720.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Wells Fargo & Company boosted their price target on shares of argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. Oppenheimer reissued an “outperform” rating and issued a $675.00 price target (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and boosted their price target for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Finally, Baird R W cut shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $661.17.

argenx Trading Down 0.0 %

argenx stock opened at $624.67 on Friday. The firm’s 50 day simple moving average is $642.61 and its 200 day simple moving average is $589.72. The firm has a market capitalization of $37.96 billion, a PE ratio of -709.85 and a beta of 0.58. argenx has a 1-year low of $349.86 and a 1-year high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Research analysts forecast that argenx will post 3.13 earnings per share for the current year.

Institutional Investors Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company’s stock worth $3,455,207,000 after purchasing an additional 824,750 shares during the period. Janus Henderson Group PLC lifted its position in shares of argenx by 0.4% in the 3rd quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after purchasing an additional 10,975 shares during the period. Capital World Investors lifted its position in shares of argenx by 5.1% in the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company’s stock worth $1,099,002,000 after purchasing an additional 86,687 shares during the period. RTW Investments LP lifted its position in shares of argenx by 2.9% in the 4th quarter. RTW Investments LP now owns 673,497 shares of the company’s stock worth $414,201,000 after purchasing an additional 19,067 shares during the period. Finally, Clearbridge Investments LLC lifted its position in shares of argenx by 6.8% in the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock worth $387,344,000 after purchasing an additional 40,330 shares during the period. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.